Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) EBT Margin (2016 - 2025)

Historic EBT Margin for Coherus Oncology (CHRS) over the last 12 years, with Q3 2025 value amounting to 384.73%.

  • Coherus Oncology's EBT Margin rose 4017700.0% to 384.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 21.98%, marking a year-over-year increase of 2490000.0%. This contributed to the annual value of 10.68% for FY2024, which is 1033000.0% up from last year.
  • Latest data reveals that Coherus Oncology reported EBT Margin of 384.73% as of Q3 2025, which was up 4017700.0% from 437.51% recorded in Q2 2025.
  • Coherus Oncology's 5-year EBT Margin high stood at 79.66% for Q4 2024, and its period low was 2947.83% during Q1 2024.
  • In the last 5 years, Coherus Oncology's EBT Margin had a median value of 159.83% in 2022 and averaged 368.2%.
  • As far as peak fluctuations go, Coherus Oncology's EBT Margin tumbled by -27143600bps in 2024, and later surged by 23240900bps in 2025.
  • Coherus Oncology's EBT Margin (Quarter) stood at 62.34% in 2021, then plummeted by -108bps to 129.81% in 2022, then surged by 33bps to 87.03% in 2023, then surged by 192bps to 79.66% in 2024, then plummeted by -583bps to 384.73% in 2025.
  • Its last three reported values are 384.73% in Q3 2025, 437.51% for Q2 2025, and 623.74% during Q1 2025.